<- Go home

Added to YB: 2024-02-16

Pitch date: 2024-02-14

CPH.TO [bullish]

Cipher Pharmaceuticals Inc.

+169.44%

current return

Author Info

Raging Bull Investments is a lawyer by background who shares actionable investment ideas on value opportunities with a catalyst. Sign up for the newsletter.

Company Info

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients.

Market Cap

CAD 330.8M

Pitch Price

CAD 7.10

Price Target

20.00 (+5%)

Dividend

N/A

EV/EBITDA

13.65

P/E

12.45

EV/Sales

6.52

Sector

Pharmaceuticals

Category

value

Show full summary:
Unlocking the Value of Cipher Pharmaceuticals

CPH.TO: Compelling asymmetric opportunity w/ $20 PT. Low EV of C$100M @ 20%+ FCF yield enables M&A & buybacks. Epuris leads Canadian acne market w/ 45% share. CEO's 40%+ stake aligns interests. MOB-015 nail fungus drug to drive EBIT from $9M to $32M by FY27, implies $18/share. Approval expected by 2025. Pipeline + cheap multiple = margin of safety & upside.

Read full article (3 min)